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serBACKGROUND Transcatheter aortic valve replacement (TAVR) enables treatment of high-risk patientswith symptomatic
aortic stenosis without open-heart surgery; however, the beneﬁts are mitigated by the potential for neurological events.
OBJECTIVES This study sought to determine the timing and causes of clinically relevant neurological events after self-
expandable TAVR.
METHODS We enrolled 1,015 patients, of whom 996 underwent TAVR with a self-expandable system at 44 TAVR-
experienced centers in Europe, Colombia, and Israel. Neurological events were evaluated for 3 distinct time periods:
periprocedural (0 to 1 days post TAVR); early (2 to 30 days); and late (31 to 730 days). In this real-world study,
neurological events were ﬁrst referred to the site neurologist and then reviewed by an independent neurologist.
RESULTS The overall stroke rate was 1.4% through the ﬁrst day post-procedure, 3.0% at 30 days, and 5.6% at 2 years.
There were no signiﬁcant predictors of periprocedural stroke or stroke/transient ischemic attack (TIA) combined.
Signiﬁcant predictors of early stroke were acute kidney injury (p ¼ 0.03), major vascular complication (p ¼ 0.04), and
female sex (p ¼ 0.04). For stroke/TIA combined, prior atrial ﬁbrillation (p ¼ 0.03) and major vascular complication
(p ¼ 0.009) were predictive. Coronary artery bypass graft surgery was the only signiﬁcant predictor of late stroke
(p ¼ 0.007) or late stroke/TIA (p ¼ 0.06).
CONCLUSIONS Treatment of high-risk patients with aortic stenosis using a self-expandable system was associated with a
low stroke rate at short- and long-term follow-up. Multivariable predictors of clinically relevant neurological events
differed on the basis of the timing after TAVR. (CoreValve Advance International Post Market Study; NCT01074658)
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210A ortic valve stenosis is the most com-mon acquired valvular heart disor-der in the elderly. Despite advances
in cardiac surgery and low mortality rates af-
ter surgical aortic valve replacement (SAVR),
up to one-third of patients with symptomatic
aortic stenosis are not considered for SAVR,
often due to frailty or comorbidities (1).
Transcatheter aortic valve replacement
(TAVR) enables treatment of aortic stenosis
without open-heart surgery. Recently, TAVR
using the balloon-expandable Sapien valve
(Edwards Lifesciences, Irvine, California) or
the self-expanding CoreValve bioprosthesis
(Medtronic, Inc., Minneapolis, Minnesota)has been shown to be superior to standard medical
therapy for inoperable patients and to be at least
noninferior to SAVR in high-risk patients with severe
symptomatic aortic stenosis (2–5).SEE PAGE 218The beneﬁts associated with the application of
TAVR, however, are mitigated by the potential of
major, disabling stroke with associated increased
mortality and early reduced quality of life (6). Despite
rapid adoption of this technology into clinical prac-
tice, reports from recent randomized controlled clin-
ical trials have raised safety concerns regarding an
increased risk of neurological events with TAVR
compared to both medical treatment and conven-
tional SAVR. In patients undergoing TAVR with the
Sapien valve from the PARTNER (Placement of Aortic
Transcatheter Valves) trials, 30-day rates of stroke or
transient ischemic attack (TIA) of 6.7% for inoperable
patients and 5.5% in patients deemed at high risk
were reported (7,8). These same studies reported
30-day rates of stroke or TIA of 1.7% with medical
management alone and 2.4% with SAVR. In the ran-
domized CoreValve US Pivotal High Risk Trial, the
rate of any stroke was numerically higher in the sur-
gical group than in the TAVR group (6.2% vs. 4.9%)s, Medtronic, and Johnson & Johnson. Dr. Gerckens has received
nses from Medtronic and Edwards Lifesciences; and has served
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is manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
received January 20, 2015; revised manuscript received April 1,at 30 days (4). However, for an already rapidly
expanding treatment modality, data coming from
carefully monitored, very large “real-world” patient
cohorts are still relatively scarce and complementary
to randomized trial data. The CoreValve ADVANCE
Study was designed to evaluate clinical outcomes,
including stroke and TIA, in real-life patients at
experienced implanting centers (excluding possible
“learning curve” inﬂuences). All adverse event adju-
dication occurred by an independent Clinical Events
Committee according to the original deﬁnitions of the
Valve Academic Research Consortium (VARC-1) (9).
The aim of this speciﬁc analysis was to characterize
the incidence, timing, type, and predictors of clini-
cally relevant neurological events in “real-life” self-
expandable system TAVR patients out to 2 years after
the procedure.
METHODS
The ADVANCE study methods, procedures, and a
detailed description of the study device (CoreValve
Transcatheter Aortic Valve, Medtronic, Inc., Minne-
apolis, Minnesota) have been previously described
(5). In brief, ADVANCE is a prospective, multicenter,
fully monitored, nonrandomized study that included
44 sites in 12 countries in Europe, Israel, and
Colombia. Each investigational site was required to
have performed at least 40 TAVR procedures to be
considered. A heart team, comprising at least 1 TAVR-
experienced interventional cardiologist and 1 cardio-
thoracic surgeon, determined the surgical risk status
and study eligibility of each patient.
The aim of the ADVANCE study was to evaluate
clinical outcomes after treatment with a self-
expandable system in real-world practice. Therefore
the exclusion criteria were limited to patients
participating in another trial that would interfere
with routine practice and patients who were unwill-
ing or unable to provide written informed consent.
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211event after TAVR was related to unique or competing
causes by evaluating the incidence and predictors of
stroke, and the composite of stroke and TIA, at 3
distinct time intervals: periprocedural (0 to 1 day
post-TAVR); early (2 to 30 days); and late (31 to 730
days). We also evaluated the effect of stroke after
TAVR on survival through 2 years.
The implanting physician chose the methods used
to evaluate the size of the access vessels and aortic
annulus. In this study, a self-expandable system was
implanted via an 18-F delivery catheter, and 26 mm
and 29 mm valve sizes were implanted to treat native
aortic valve annuli of 20 to 27 mm in diameter. Pro-
cedural decisions, such as access site, anesthesia
type, and, if needed, maneuvers performed after
valve placement, such as post-TAVR balloon dilation,
were left to the discretion of the heart team and pri-
mary operator. Patients received heparin during the
procedure and dual antiplatelet therapy (aspirin and
clopidogrel) was recommended for 6 months post-
operatively. Warfarin anticoagulation and the dura-
tion of antiplatelet therapy were left to the discretion
of the local physicians and local hospital-based stan-
dard protocols.
In the case of a suspected neurological event
(stroke/TIA) on the basis of clinical evaluation of the
local heart team, a systematic consultation of an
on-site neurologist was performed. Finally, these
events were then systematically reviewed by an in-
dependent neurologist to provide detailed, additional
documentation for the Clinical Event Committee to
be able to adjudicate the events. Major and minor
strokes, as well as TIA, were deﬁned according to
VARC-1 (9). Stroke was deﬁned as a rapid onset of a
focal or global neurological deﬁcit with change
in level of consciousness, hemiplegia, hemiparesis,
numbness or sensory loss affecting 1 side of the body,
dysphasia or aphasia, hemianopia, amaurosis fugax,
or other neurological signs or symptoms consistent
with stroke and conﬁrmed by a neurology specialist as
well as neuroimaging. TIA was deﬁned as a new focal
neurological deﬁcit as indicated above with rapid
symptom resolution within 24 h in the absence of
cerebral tissue injury as evidenced by neuroimaging.
The Clinical Events Committee used the neurolo-
gist’s assessment, along with any other patient source
data, to adjudicate the events.
The deﬁnition of prior atrial ﬁbrillation (AF) was
based on medical history from the case report form,
site-reported electrocardiograms (ECG), and core
lab-analyzed ECGs available prior to the start of the
given window (i.e., only considered medical history
and baseline ECGs for the 0- to 1-day window;
considered medical history, baseline, post-procedure,and discharge ECGs for the 2- to 30-day window; and
considered medical history, baseline, post-procedure,
discharge, and 1-month ECGs for the 31- to 730-day
window). The database does not provide adequate
information regarding whether AF was paroxysmal,
permanent, or persistent.
STATISTICAL ANALYSIS. We report categorical vari-
ables as n and % and continuous variables as
mean  SD. Characteristics were compared between
groups using Student t tests for continuous variables
and chi-square or Fisher exact tests, where appro-
priate, for categorical variables. Freedom-from-
mortality curves were generated by the Kaplan-Meier
method and comparisons between groups were calcu-
lated using the log-rank test. For Kaplan-Meier curves,
time zero is deﬁned as the date of the procedure. For
patients without an event, the date of censoring was
the latest date of all follow-up visits (including study
exit) and events (including death). Hazard ratios, 95%
conﬁdence intervals (CIs), and p values are presented
for univariable andmultivariable predictor analyses on
the basis of proportional hazards models.
For the predictor analysis, we identiﬁed potential
predictors on the basis of clinical judgment for each
of the 3 time intervals. Only the ﬁrst event per patient
was evaluated. The number at risk at the beginning of
each time period is the number of patients free from a
neurological event at the start of the time period and
who had follow-up data available. Therefore, patients
with an event in an earlier time period are excluded
from the risk set in later time periods. For the pro-
cedural time interval, we included patient baseline
characteristics and medical history in the list of po-
tential predictors. For the early time interval, in
addition to the baseline and history variables, we
added procedural characteristics (e.g., anesthesia
route, procedure duration), procedural complica-
tions, and any adverse event that occurred during or
after the TAVR procedure but before the neurological
event. Last, for the late time interval we included
baseline characteristics, medical history, and prior
adverse events, but excluded those considered
related to the procedure. We only included the ﬁrst
neurological event per patient.
In the selection process of potential predictors, we
also excluded rare characteristics or events that
occurred in #5% of the total risk set for a given time
interval. Statistically signiﬁcant variables with a
p value <0.20 from the univariable analyses were
included in stepwise selection to determine the ﬁnal
multivariable model. Procedural complications and
adverse events were included as time-dependent
covariates. The ﬁnal multivariable model included
any predictors with a p value <0.10. All analyses were
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212performed using SAS version 9.3 software (SAS Insti-
tute Inc., Cary, North Carolina).
RESULTS
From March 2010 through July 2011, 1,015 patients
were enrolled in the ADVANCE study, of whom 996
had an attempted implant with the self-expandable
system. Mean age was 81.1  6.4 years, 51% were fe-
male, 79.6% of patients had New York Heart Associ-
ation functional class III or IV symptoms, and 13.1%
had cerebrovascular disease at baseline.
The overall rate of stroke was 1.4% through the ﬁrst
day post-procedure, 3.0% at 30 days, and 5.6% at
2 years; with major stroke rates of 0.5%, 1.2%, and
2.9% for the same time periods, respectively.
No statistically signiﬁcant differences were found
between the patients who developed a stroke or a
stroke/TIA and patients who did not develop a peri-
procedural neurological event (all p >0.05). Online
Tables 1 and 2 summarize baseline characteristics
for patients with and without a stroke and those with
and without stroke/TIA in the immediate post-
procedural period (0 to 1 days post-TAVR), along
with the univariable proportional hazard models
results.
Patients with early stroke were more often female
(81.3% vs. 49.8%; p ¼ 0.02), had higher Society of
Thoracic Surgeons (STS) scores (8.7  4.8% vs. 6.3 
4.3%; p ¼ 0.04), and more frequently had a major
vascular complication (31.3% vs. 11.1%; p ¼ 0.01) after
TAVR. Patients with early stroke/TIA had similarFrom Stroke and TIA
Days 1 Year 2 Years
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97.7%
98.1%
97.1%
97.0%
Major Stroke
Minor Stroke
TIA
er curves demonstrate, incidence of any type of neurological event
ears in the ADVANCE study. TIA ¼ transient ischemic attack.differences: STS score (8.5  4.7% vs. 6.3  4.4%; p ¼
0.04) and major vascular complication (29.4% vs.
11.0%; p ¼ 0.02). Baseline and procedural character-
istics are summarized for patients with and without
an early (2 to 30 days post-TAVR) stroke or stroke/
TIA, and univariable proportional hazards models
results are shown in Online Tables 3 and 4.
Patients with late stroke more frequently had prior
coronary artery bypass grafting (CABG) (47.6% vs.
21.0%; p ¼ 0.003), which was also true for patients
with a late stroke/TIA (35.3% vs. 21.0%; p ¼ 0.047).
Summaries by group and univariable proportional
hazards models results are shown in Online Tables 5
and 6.
CLINICALLY RELEVANT NEUROLOGICAL EVENTS.
Figure 1 shows Kaplan-Meier freedom from major and
minor stroke, and TIA through 2 years. Overall, 14
patients had a stroke in the early periprocedural
period, and 2 patients had a TIA. From 2 to 30 days
post-procedure, an additional 16 patients experi-
enced a stroke and 1 patient had a TIA. During the late
post-procedural period, 21 patients had a stroke and
an additional 13 patients had a TIA. At each time
point, the majority of stroke events were ischemic in
origin (Figure 2).
We also evaluated the effect of valve implant ac-
cess route on stroke and stroke/TIA events in the
early time period after TAVR. There were no signiﬁ-
cant differences in the rate of stroke or in the rate of
stroke or TIA on the basis of access (Online Table 4).
Survival through 2 years for patients with and
without a stroke, and for those with and without a
stroke/TIA, within the ﬁrst 30 days post-TAVR is
shown in Figure 3.
PREDICTORS OF STROKE OR STROKE/TIA. None of
the univariable predictors examined (Online Table 1)
met the alpha level criterion of <0.20 to be consid-
ered for the multivariable predictor analysis for per-
iprocedural stroke. The predictors of early and late
stroke are reported in Table 1. In the multivariable
model, besides female sex, the occurrence of acute
kidney injury and major vascular complication were
identiﬁed as signiﬁcant independent predictors of
early stroke. Prior CABG was the only signiﬁcant in-
dependent predictor of late stroke.
We also did not identify any multivariable pre-
dictors of periprocedural stroke/TIA events combined
on the basis of our model selection criteria. The pre-
dictors of early and late stroke or TIA are reported in
Table 2. In the multivariable model, prior AF and
major vascular complication were identiﬁed as sig-
niﬁcant independent predictors of early stroke/TIA.
Prior CABG was also a signiﬁcant independent pre-
dictor of late stroke/TIA.
FIGURE 2 Type of Stroke Over Time
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213DISCUSSION
The CoreValve ADVANCE study, the largest, multi-
center, prospective, fully monitored, VARC-reported
“real-world” CoreValve study, has already reported
improvement in aortic valve function and quality of
life with low mortality rates at 1 and 12 months after
TAVR (5). In our analyses, the incidence of stroke or
stroke/TIA during the immediate periprocedural time
period, as well as within 1 month or through 2 years
after valve replacement, all proved to be relatively
low, taking into account the age and risk proﬁle of
this high-risk patient cohort. However, we found that
the occurrence of a clinically relevant neurological
event within the ﬁrst month post-procedure signiﬁ-
cantly affected long-term survival, highlighting the
importance of these types of analyses to uncover
clinically meaningful predictors that can aid in pa-
tient selection for TAVR.
Of the neurological events that occurred within
the ﬁrst month after TAVR, only one-half occurred in
the periprocedural time period (days 0 to 1), with the
remainder documented on days 2 to 30 post-
procedure. Most strokes, regardless of the time since
the procedure, were ischemic and only rarely hem-
orrhagic (Figure 2). We were not able to identify any
predictors of periprocedural stroke. For the early time
period (days 2 to 30), acute kidney injury, female sex,
and major vascular complication predicted stroke.
When considering stroke and TIA together, history ofFIGURE 3 Survival on the Basis of Neurological Event Status
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In the ADVANCE study, the incidence of stroke
after (mostly transfemoral) TAVR, even in “real-
world” patients, was lower compared to the relatively
recently published stroke data from both the
PARTNER and CoreValve US Pivotal trials (2–4). In
the PARTNER trial, the rate of neurological events in
high-risk patients treated transfemorally was 3 times
higher after TAVR than after SAVR: 4.6% versus 1.4%2 Years
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without a stroke event (A) or a stroke/transient ischemic attack (TIA) event (B) within the ﬁrst
ho did not experience a stroke or TIA within the ﬁrst 30 days post-TAVR had signiﬁcantly
TABLE 1 Predictors of Early and Late Stroke After TAVR*
Event No Event
Univariable Analysis† Multivariable‡
HR 95% CI p Value HR 95% CI p Value
Predictors of early (2–30 days) stroke post-TAVR (event, n ¼ 16; no event, n ¼ 959)
Male (vs. female) 18.8 (3/16) 50.2 (481/959) 0.23 0.07–0.82 0.023 0.26 0.07–0.92 0.037
STS mortality, %§ 8.7  4.8 (16) 6.3  4.3 (958) 1.62 0.82–3.22 0.129
STS mortality <4% (vs. 4%–10%) 6.3 (1/16) 31.1 (298/958) 0.17 0.02–1.28 0.085
STS mortality 4%–10% (vs. >10%) 68.8 (11/16) 56.3 (539/958) 0.63 0.20–1.98 0.631
STS mortality >10% (vs. <4%) 25.0 (4/16) 12.6 (121/958) 9.60 1.07–85.85 0.043
Prior AF 56.3 (9/16) 37.2 (357/959) 2.18 0.81–5.85 0.122
Prior CABG 6.3 (1/16) 21.5 (206/956) 0.25 0.03–1.86 0.174
Acute kidney injury 18.8 (3/16) 7.4 (71/959) 5.04 1.43–17.77 0.012 4.32 1.19–15.64 0.026
Major vascular complication 31.3 (5/16) 11.1 (106/959) 4.47 1.55–12.85 0.006 3.12 1.04–9.31 0.042
Predictors of late (31–730 days) stroke post-TAVR (event, n ¼ 21; no event, n ¼ 905)
Age 78.7  7.9 (21) 81.0  6.4 (905) 0.96 0.90–1.01 0.137
Prior CABG 47.6 (10/21) 21.0 (189/902) 3.26 1.38–7.67 0.007 3.26 1.38–7.67 0.007
Acute kidney injury 14.3 (3/21) 6.7 (61/905) 3.61 1.06–12.26 0.040
Values are % (n/N) or mean  SD (n). *For the very early time period of days 0 to 1 post-transcatheter aortic valve replacement (TAVR), no predictors of stroke were found. †An alpha level of
0.20 was used to select univariable predictors. ‡Hazard ratios and p values are adjusted for the other covariates in the ﬁnal model. §The p value is from Type III tests for comparisons across
categorical groups.
AF ¼ atrial ﬁbrillation; CABG ¼ coronary artery bypass grafting; CI ¼ conﬁdence interval; HR ¼ hazard ratio; STS ¼ Society of Thoracic Surgeons.
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214at 30 days and 6.1% versus 1.9% at 1 year (10). How-
ever, the patients in the ADVANCE real-world study
were at lower risk (as expressed by lower mean STS
score) than in either PARTNER trial, with a lower
incidence of pre-existing cerebrovascular disease.
Also, the relatively good survival, even in the patient
cohort that sustained a neurological complication
(Figure 3), compared to that in the PARTNER studies,
may reﬂect the fact that ADVANCE patients were
less sick, frail, or debilitated. Moreover, in ADVANCE,
all patients were treated in relative high-volume
TAVR sites. In the CoreValve US Pivotal High
Risk trial, which included somewhat higher-riskTABLE 2 Predictors of Early and Late Stroke or TIA After TAVR
Event No Eve
Predictors of early (2–30 days) stroke or TIA post-TAVR (event, n ¼ 17; no
Male (vs. female) 29.4 (5/17) 50.1 (4
STS mortality (%)‡ 8.5  4.7 (17) 6.3  4.4 (9
STS mortality <4% (vs. 4%–10%) 5.9 (1/17) 31.1 (2
STS mortality 4%–10% (vs. >10%) 70.6 (12/17) 56.2 (5
STS mortality >10% (vs. <4%) 23.5 (4/17) 12.7 (1
Prior AF 64.7 (11/17) 37.1 (3
Acute kidney injury 17.6 (3/17) 7.4 (7
Bleeding event 41.2 (7/17) 32.8 (3
Major vascular complication 29.4 (5/17) 11.0 (1
Predictors of late (31–730 days) stroke or TIA post-TAVR (event, n ¼ 34; n
Prior CABG 35.3 (12/34) 21.0 (1
Major bleed 2.9 (1/34) 12.3 (1
Values are % (n/N) or mean  SD (n). *An alpha level of 0.20 was used to select univaria
ﬁnal model. ‡p value is from Type III tests for comparisons across the categorical group
TIA ¼ transient ischemic attack; other abbreviations as in Table 1.patients treated at less experienced TAVR sites, the
cumulative frequency of all strokes at 1 year was 8.8%
compared to 12.6% in the surgical group (4). Yet in the
CoreValve US trial at least all patients had a National
Institutes of Health stroke status assessment before
and after the procedure and any change triggered
a neurological evaluation and imaging. This also
may contribute to the higher rate seen compared
with ADVANCE.
The SOURCE XT Registry, which enrolled “real-
world” patients treated with the Sapien XT trans-
catheter valve (Edwards Lifesciences) at about the
same time as the ADVANCE study, recently reportednt
Univariable Analysis* Multivariable†
HR 95% CI p Value HR 95% CI p Value
event, n ¼ 956)
79/956) 0.42 0.15–1.20 0.105
55) 0.129
97/955) 0.15 0.02–1.17 0.070
37/955) 0.69 0.22–2.14 0.521
21/955) 9.56 1.07–85.55 0.043
55/956) 3.11 1.15–8.40 0.026 3.02 1.12–8.17 0.030
1/956) 5.16 1.47–18.13 0.011
14/956) 1.99 0.76–5.24 0.162
05/956) 4.15 1.46–11.77 0.008 3.99 1.41–11.34 0.009
o event, n ¼ 889)
86/886) 1.96 0.97–3.95 0.062 1.96 0.97–3.95 0.062
09/889) 0.27 0.04–1.95 0.193
ble predictors. †Hazard ratios and p values are adjusted for the other covariates in the
s.
CENTRAL ILLUSTRATION Timing, Number, and Predictors of Clinically Relevant Stroke/TIA
Bosmans, J. et al. J Am Coll Cardiol. 2015; 66(3):209–17.
Approximately the same number of neurological events occurred within the periprocedural time period (days 0 to 1) as did during the
remainder of the ﬁrst month after transcatheter aortic valve replacement (TAVR). Unsurprisingly, such events rose over the next 2 years
post-TAVR. History of atrial ﬁbrillation (AF) and major vascular complication were signiﬁcant predictors of early neurological events, and a
history of coronary artery bypass graft surgery (CABG) was a signiﬁcant predictor of late neurological events. Percentages represent the
number of patients with an event out of the number at risk at the beginning of the time interval. These are simple proportions and will not
completely align with the Kaplan-Meier rates, which censor patients and take into account events over time. TIA ¼ transient ischemic attack.
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215higher stroke rates through 2 years (11). These dis-
crepancies are not easily explained by differences in
patient risk proﬁle given that the logistic EuroSCORE
in ADVANCE was similar to the SOURCE XT Registry,
although our study included fewer patients implan-
ted via a noniliofemoral access route. The fact that
ADVANCE and SOURCE XT were performed exclu-
sively in high-volume TAVR sites excludes the effect
of possible “learning-curve” inﬂuences, at least for
these 2 studies, and standard clinical practice would
have been similarly applied. Access route, delivery
system size, and valve type as well as the criteria for
stroke assessment varied among these studies and
may have contributed alone or in combination to the
differences in overall event rates.
MECHANISMS OF STROKE AFTER TAVR. Periproce-
dural stroke, accounting for about 30% of strokes after
implantation, has a multifactorial etiology. In our
analysis, no speciﬁc patient or procedure-related
characteristics could be identiﬁed as a signiﬁcantpredictor for periprocedural stroke. However, most
probably, catheter manipulations of the calciﬁed and
diseased aortic valve and aortic arch cause emboliza-
tion of aortic debris or thrombotic material, resulting
in stroke or TIA (12). Therefore, embolic protection
devices currently under evaluation might offer po-
tential beneﬁt in reduction of at least some of TAVR-
related neurological complications.
Remarkably, in ADVANCE, 50% of the strokes that
occurred within the ﬁrst 30 days after TAVR were
recognized after the ﬁrst 2-day periprocedural win-
dow. Also in the PARTNER trial TAVR-treated high-
risk patients, 6 of the 18 neurologic events (TIA,
minor or major stroke) that occurred within the ﬁrst
month presented after the 0- to 2-day window (10).
These observations strongly suggest that other de-
terminants, apart from procedural aspects, are
signiﬁcantly related to ﬁnal neurological outcome.
Indeed, female sex (most probably by smaller arterial
vessel diameter and increased risk of vascular
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Although TAVR has become a standard management
strategy for patients with symptomatic aortic valve
stenosis facing a high risk of complicationswith SAVR, a
history of atrial ﬁbrillation or CABG identify patients
with a higher risk of stroke during themonth after TAVR
with a self-expandable valve prosthesis at centers with
experience performing $40 TAVR procedures.
TRANSLATIONAL OUTLOOK: Additional study is
needed to evaluate the generalizability of these cor-
relations to patients undergoing TAVR at less experi-
enced centers requires, and large registry databases
could be employed for this purpose as the technique
becomes more widely employed.
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216complications), history of AF, acute kidney injury, or
major vascular complication after TAVR (most likely
due to prolonged hypotensive episodes) all signiﬁ-
cantly predicted early neurological events.
ADVANCE suggests that a history of AF may be
an important risk factor for neurological events
(stroke/TIA) early after TAVR. These results strongly
suggest that, in order to reduce neurological com-
plications after TAVR, anticoagulation therapy
should be started immediately after diagnosis of the
AF episode and continued for several months. No
clear guidelines actually exist on anticoagulation
therapy after short episodes of postoperative AF
(13). However, patients undergoing TAVR are at
high risk for thromboembolism in cases of atrial
arrhythmia, and a more aggressive antithrombotic
treatment should probably be implemented in these
cases. Although dual antiplatelet therapy with
aspirin and clopidogrel has been empirically rec-
ommended after TAVR, future randomized studies
will have to evaluate the more appropriate antith-
rombotic treatment after these procedures and the
potential role for systematic anticoagulant therapy
either with warfarin or direct thrombin inhibitors in
this setting.
The only signiﬁcant predictor of late neurological
events, occurring >1 month after TAVR, was a history
of CABG, most likely reﬂecting more extensive
or complex atherosclerotic disease. Also in the
PARTNER trial TAVR-treated high-risk patients, the
likelihood of late neurologic events was linked to
patient-related factors. Late strokes after TAVR
therefore seem to be mostly related to patient-
dependent characteristics and not to valve- or
procedure-related factors, at least through 2 years
after implantation.
STUDY LIMITATIONS. The relatively low rate of ce-
rebrovascular events, despite this large patient
cohort, has to be considered when interpreting the
results of the present study. The low number of
events may result in difﬁculty identifying predictors
and cause overﬁtting of the proportional hazards
models. In this real-world study, a neurologist was
consulted after a clinically relevant neurological
event was ﬁrst suspected by the local heart team—
much as would occur in standard clinical practice—
which could have also contributed to the low docu-
mented cerebrovascular event rate, especially
compared to other large trials. It is possible that the
comorbid condition of our study population might
have diluted the impact of TAVR on stroke. In addi-
tion, the “real-life” nature of this study did not
include close monitoring of patient compliance
with anticoagulation and antiplatelet medications;therefore we were not able to determine any rela-
tionship with the timing or type of stroke events.
CONCLUSIONS
Multivariable analyses of time-related potential pre-
dictors were not able to identify any predictors of
periprocedural neurological events. During the early
post-procedural period, predictors of neurological
events varied depending on whether stroke was
considered alone or stroke and TIA were considered
together. The only predictor of late events was a
history of CABG, probably reﬂecting patient risk and
not the TAVR procedure. The overall incidence of
clinically relevant neurological events was low in the
ADVANCE Study through 2 years after TAVR with the
self-expandable system.
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